Somewhat Favorable News Coverage Somewhat Unlikely to Impact Invuity (IVTY) Stock Price
News stories about Invuity (NASDAQ:IVTY) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invuity earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 45.7802392445828 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Invuity (IVTY) and Ekso Bionics Holdings (EKSO) Financial Review (americanbankingnews.com)
- Invuity, Inc. (IVTY) Rating Increased to Sell at ValuEngine (americanbankingnews.com)
- Invuity, Inc. (IVTY) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Invuity, Inc. (IVTY) Appoints Daniel Wolterman to Board (streetinsider.com)
Invuity (NASDAQ IVTY) remained flat at $8.25 during trading on Thursday. The company had a trading volume of 24,867 shares. The firm’s 50 day moving average price is $7.14 and its 200-day moving average price is $7.66. Invuity has a one year low of $4.50 and a one year high of $14.25. The firm’s market cap is $140.66 million.
Invuity (NASDAQ:IVTY) last posted its earnings results on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.07. The company had revenue of $9.77 million for the quarter, compared to the consensus estimate of $10.30 million. Invuity had a negative return on equity of 140.69% and a negative net margin of 114.61%. On average, analysts predict that Invuity will post ($2.38) EPS for the current fiscal year.
IVTY has been the subject of a number of recent research reports. Northland Securities reissued a “buy” rating and set a $13.00 price target on shares of Invuity in a research report on Tuesday, May 16th. Zacks Investment Research lowered shares of Invuity from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. Piper Jaffray Companies reissued a “buy” rating and set a $10.00 price target on shares of Invuity in a research report on Wednesday, July 26th. William Blair reissued a “buy” rating on shares of Invuity in a research report on Tuesday, May 23rd. Finally, ValuEngine raised shares of Invuity from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Invuity has an average rating of “Hold” and a consensus price target of $13.20.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Invuity (IVTY) Stock Price” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-invuity-ivty-stock-price.html.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Stock Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related stocks with our FREE daily email newsletter.